Jiangxi Institute of Biological Products Inc. Launches Veterinary Tetanus Antitoxin Production Line, Marking Strategic Expansion in Animal Health
Key Points:
- Chifeng Bo-en Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Jiangxi Institute of Biological Products Inc., has officially commenced production of its veterinary tetanus antitoxin (Veterinary TAT) production line on July 20, 2026, in Chifeng City, Inner Mongolia.
- The production line focuses on Veterinary TAT, used for the prevention and treatment of tetanus in animals, a fatal infectious disease caused by the toxin of Clostridium tetani.
- This milestone is part of the Group’s “human pharmaceuticals + veterinary pharmaceuticals” dual-wheel-driven strategy, signaling a significant diversification and expansion of its antiserum product portfolio from human health into the animal health sector.
- The new production line provides production capacity assurance for large-scale manufacturing and commercial promotion of veterinary antiserum products.
- Chifeng Bo-en operates a modern veterinary pharmaceutical production system compliant with China’s new Veterinary GMP standards, EU GMP, and US FDA quality systems.
- The facility includes three production zones and eight modern production lines covering antisera, cell fermentation, biological extraction, and chemical preparations, with a diversified product portfolio.
- Products include: veterinary tetanus antitoxin, recombinant interferon-α, pig spleen transfer factor, bursal peptide, and reproductive hormones. R&D and industrialization of new veterinary antisera and innovative products are ongoing.
Implications for Shareholders and Potential Investors
- This development positions Jiangxi Institute of Biological Products Inc. as a leading player in both human and animal pharmaceutical markets, potentially accelerating revenue growth and improving market competitiveness.
- The expansion into animal health pharmaceuticals, especially with a modern GMP-compliant facility, may strengthen business growth momentum and enhance shareholder value.
- The launch of the Veterinary TAT production line could be price-sensitive and positively affect the share value, given the growing global demand for veterinary medicines and the Group’s enhanced production capabilities.
- The announcement signals a commitment to ongoing innovation in veterinary pharmaceuticals, which may attract new investments and strategic partnerships.
- This strategic move marks a key advancement in the Group’s dual-wheel strategy, providing assurance for large-scale production and commercial promotion, effectively enriching the Group’s multi-category antiserum portfolio.
Board Composition
The Board comprises:
- Executive Directors: Ms. Jing Yue (Chairperson), Mr. Yao Xiaodong, Mr. Li Changqing, Ms. Jing Ruihua
- Non-executive Directors: Ms. Yu Ailian, Mr. Xiao Changqing
- Independent Non-executive Directors: Dr. Zou Pingxue, Dr. Tsang Hiu Leong, Mr. Wu Di
Conclusion
This announcement represents a major milestone for Jiangxi Institute of Biological Products Inc. by expanding its footprint into the lucrative veterinary pharmaceutical sector with a state-of-the-art production facility. Shareholders should monitor future developments closely as this could materially influence the company’s growth trajectory and share price.
Disclaimer: The above article is based on information provided by Jiangxi Institute of Biological Products Inc. as of July 27, 2026. Investors should conduct their own due diligence and consult with professional advisers before making investment decisions. This article does not constitute investment advice.
江西生物製品研究所股份有限公司啟動獸用破傷風抗毒素生產線 戰略擴展動物健康領域
重點：
- 赤峰博恩製藥有限公司（公司全資子公司）於2026年7月20日在內蒙古赤峰市正式啟動獸用破傷風抗毒素生產線。
- 新生產線專注於獸用破傷風抗毒素，主要用於動物因創傷或手術導致的破傷風預防和治療，破傷風為由破傷風梭菌毒素引起的致命傳染病。
- 此里程碑是集團“人用藥＋獸用藥雙輪驅動戰略”重要一步，標誌抗血清產品組合由人用領域擴展至動物健康領域。
- 新生產線為大規模生產及商業推廣獸用抗血清產品提供產能保障。
- 赤峰博恩建立了符合中國新獸藥GMP標準、歐盟GMP及美國FDA質量體系的現代獸用製藥生產系統。
- 設有三個生產區、八條現代生產線，覆蓋抗血清、細胞發酵、生物提取及化學製劑等多元生產能力。
- 產品組合包括：獸用破傷風抗毒素、重組干擾素-α、豬脾轉移因子、法氏囊肽及生殖激素等，並持續推進獸用抗血清及創新產品研發和產業化。
對股東及潛在投資者的影響
- 此發展令江西生物製品研究所股份有限公司成為人用及獸用藥品市場領先者，有望加速收入增長及提升市場競爭力。
- 動物健康藥品擴展及現代GMP合規設施，有望增強業務增長動力及提升股東價值。
- 獸用破傷風抗毒素生產線啟動可能具價格敏感性，隨著全球獸用藥需求增長，集團產能提升或正面影響股價。
- 公告顯示集團持續創新獸用藥品，或吸引新投資及戰略合作。
- 此舉為雙輪戰略關鍵進展，為大規模生產及商業推廣提供保障，豐富多類抗血清組合。
董事會組成
- 執行董事：景悅女士（董事長）、姚曉東先生、李長青先生、景瑞華女士
- 非執行董事：余愛蓮女士、肖長青先生
- 獨立非執行董事：鄒平學博士、曾曉亮博士、吳迪先生
結論
本公告標誌江西生物製品研究所股份有限公司進軍獸用藥品領域的重要里程碑，股東應密切關注未來發展，此舉或對公司增長及股價產生實質影響。
免責聲明：本文資訊來源於江西生物製品研究所股份有限公司截至2026年7月27日之公告。投資者應自行進行盡職調查並諮詢專業顧問後作出投資決策。本文不構成投資建議。
